Trilogy Capital’s GSK GSK Stock Holding History

Trilogy Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,648	Closed	-$688K	–	181
2022 Q2	$688K	Buy	+12,648	New	+$698K	0.06%	107
2018 Q4	–	Sell	-320	Closed	-$16K	–	307
2018 Q3	$16K	Buy	320 +160	+100%	+$8.13K	﹤0.01%	288
2018 Q2	$8K	Sell	160 -60	-27%	-$3.02K	﹤0.01%	316
2018 Q1	$11K	Buy	+220	New	+$10.2K	﹤0.01%	256

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Trilogy Capital's GSK Position: Q3 2022 in Review

Trilogy Capital sold out of GSK (GSK) in Q3 2022, closing a stake of 12,648 shares — an estimated $688K sold.

Trilogy Capital first reported a position in GSK in Q1 2018 and held it in 4 quarters. The position peaked at $688K in Q2 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

Trilogy Capital reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
Trilogy Capital sold 12,648 GSK shares in Q3 2022, an estimated $688K.
Trilogy Capital first reported a position in GSK in Q1 2018 and held it in 4 quarters.
Trilogy Capital's GSK position peaked at $688K in Q2 2022.
742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Trilogy Capital's 13F filing for Q3 2022, filed 21 Oct 2022.